$ACER #AcerTherapeutics Reports Q2 2021 #FinancialResults & Provides #CorporateUpdate
​

https://preview.redd.it/9i6d4tsoaxg71.png?width=480&format=png&auto=webp&s=07a6d4b4cf2897a909c0946c29aca7692fcd1c27

# Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2021, and provided an update on the Company’s recent corporate developments.

# “This quarter marks significant, meaningful progress across our entire pipeline, including the very recent submission of our NDA for ACER-001 for the treatment of UCDs,” said Chris Schelling, CEO, and Founder of Acer. “As we anticipate working closely with the FDA on the review process for ACER-001, we continue to make significant progress across the rest of our pipeline, including preparation of two IND submissions targeted for Q4 of this year. These INDs are expected to support initiating a dose-ranging Phase 2a study for ACER-801 (osanetant) for the treatment of vasomotor symptoms, and a pivotal Phase 3 study for EDSIVO™ for the treatment of COL3A1+ vEDS. On the corporate front, we have enhanced our management team with four important senior-level hires across their respective disciplines, including program and alliance management, marketing, and clinical development. I warmly welcome our new team members, who bring deep industry knowledge and tremendous experience, and look forward to their contributions as we position ourselves for growth.”

# Read more: [https://finance.yahoo.com/news/acer-therapeutics-reports-q2-2021-200500415.html](https://finance.yahoo.com/news/acer-therapeutics-reports-q2-2021-200500415.html)
https://www.reddit.com/r/StockMarket/comments/p2z4ab/acer_acertherapeutics_reports_q2_2021/